Evidence map›Paper›PMID 32064457›Full record

ArticleJNCI cancer spectrum2020

DNA Repair Biomarker for Lung Cancer Risk and its Correlation With Airway Cells Gene Expression.

Tamar Paz-Elizur, Yael Leitner-Dagan, Kerstin B Meyer, Barak Markus, Federico M Giorgi, Martin O'Reilly, Hyunjin Kim, Yentl Evgy, Ronen Fluss, Laurence S Freedman and 3 more

Open access · goldAbstract read
In one paragraph

Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Tamar Paz-ElizurSee the Notes section for the full list of authors' affiliations.ORCID 0000-0001-8401-2508
Yael Leitner-DaganSee the Notes section for the full list of authors' affiliations.
Kerstin B MeyerSee the Notes section for the full list of authors' affiliations.ORCID 0000-0001-5906-1498
Barak MarkusSee the Notes section for the full list of authors' affiliations.
Federico M GiorgiSee the Notes section for the full list of authors' affiliations.ORCID 0000-0002-7325-9908
Martin O'ReillySee the Notes section for the full list of authors' affiliations.
Hyunjin KimSee the Notes section for the full list of authors' affiliations.ORCID 0000-0003-0947-3149
Yentl EvgySee the Notes section for the full list of authors' affiliations.
Ronen FlussSee the Notes section for the full list of authors' affiliations.
Laurence S FreedmanSee the Notes section for the full list of authors' affiliations.ORCID 0000-0002-6767-7900
Robert C RintoulSee the Notes section for the full list of authors' affiliations.ORCID 0000-0003-3875-3780
Bruce PonderSee the Notes section for the full list of authors' affiliations.
Zvi LivnehSee the Notes section for the full list of authors' affiliations.ORCID 0000-0003-1677-7677
University of Cambridge · GBWeizmann Institute of Science · ILSheba Medical Center · IL

Funding

DNA Repair Biomarkers for Cancer Risk & Early DetectionU01CA111219 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI LIVNEH, ZVI · 2005 to 2009
$1.1M
Cancer Research UK 17031NCI NIH HHS U01 CA111219
6 · The paper itself

Abstract

backgroundImproving lung cancer risk assessment is required because current early-detection screening criteria miss most cases. We therefore examined the utility for lung cancer risk assessment of a DNA Repair score obtained from OGG1, MPG, and APE1 blood tests. In addition, we examined the relationship between the level of DNA repair and global gene expression.

methodsWe conducted a blinded case-control study with 150 non-small cell lung cancer case patients and 143 control individuals. DNA Repair activity was measured in peripheral blood mononuclear cells, and the transcriptome of nasal and bronchial cells was determined by RNA sequencing. A combined DNA Repair score was formed using logistic regression, and its correlation with disease was assessed using cross-validation; correlation of expression to DNA Repair was analyzed using Gene Ontology enrichment.

resultsDNA Repair score was lower in case patients than in control individuals, regardless of the case's disease stage. Individuals at the lowest tertile of DNA Repair score had an increased risk of lung cancer compared to individuals at the highest tertile, with an odds ratio (OR) of 7.2 (95% confidence interval [CI] = 3.0 to 17.5;

conclusionsThe DNA Repair score, previously shown to be a lung cancer risk factor in the Israeli population, was validated in this independent study as a mechanism-based cancer risk biomarker and can substantially improve current lung cancer risk prediction, assisting prevention and early detection by computed tomography scanning.

Identifiers

PMID32064457
PMCPMC7012022
OpenAlexW3008720226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.